Talk:Sarepta Therapeutics

Moved from main article

Not sure if the following belongs in the article. I looked at a few other pharmaceutical company articles and they did not have this sort of info. I'm not an expert on corporate articles so please let me know if I'm wrong. If replaced, the info really needs to be cleaned up and formatted. Katr67 23:19, 21 August 2006 (UTC) Modified by Katr67 19:09, 8 December 2006 (UTC)

Key Statistics

Market Cap (intraday): 97.65M,Enterprise Value (29-Sep-05)3: 66.79M, Trailing P/E (ttm, intraday): N/A, Forward P/E (fye 31-Dec-06) 1: N/A, PEG Ratio (5 yr expected): N/A, Price/Sales (ttm): 261.09, Price/Book (mrq): 2.56, Enterprise Value/Revenue (ttm)3: 176.10, Enterprise Value/EBITDA (ttm)3: -3.556

Financial highlights

Fiscal Year Fiscal Year Ends: 31-Dec Most Recent Quarter (mrq): 30-Jun-05 Profitability Profit Margin (ttm): -5413.09% Operating Margin (ttm): -5472.21% Management Effectiveness Return on Assets (ttm): -32.97% Return on Equity (ttm): -55.04% Income Statement Revenue (ttm): 379.25K Revenue Per Share (ttm): 0.01 Qtrly Revenue Growth (yoy): 8.40% Gross Profit (ttm): 969.87K EBITDA (ttm): -18.78M Net Income Avl to Common (ttm): -20.53M Diluted EPS (ttm): -0.52 Qtrly Earnings Growth (yoy): -31.00%

Balance Sheet

Total Cash (mrq): 32.19M Total Cash Per Share (mrq): 0.728 Total Debt (mrq): 0 Total Debt/Equity (mrq): 0 Current Ratio (mrq): 16.833 Book Value Per Share (mrq): 0.874 Cash Flow Statement From Operations (ttm): -18.15M Free Cashflow (ttm): -12.69M

Key Executives & Pay Exercised

• Dr. Denis R. Burger Ph.D., 61

Chairman, Chief Exec. Officer and Member of Exec. Committee $ 450.00K $ 0

• Mr. Alan P. Timmins , 45

Pres, Chief Operating Officer, Director and Member of Exec. Committee $ 385.00K $ 0

• Mr. Mark M. Webber , 50

Chief Financial Officer, Principal Accounting Officer, Chief Information Officer and Controller $ 250.00K $ 0

• Dr. Patrick L. Iversen Ph.D., 49

Sr. VP of R&D $ 300.00K $ 0

• Dr. Dwight D. Weller Ph.D., 54

Sr. VP of Chemistry and Manufacturing, Director and Member of Exec. Committee $ 250.00K $ 0

Update

The notes above are very out-of-date, it would be reasonable to remove them from this page.

I just changed the statement that Summerton "discovered" Morpholinos so that it now states he conceived of them and then, with Weller, invented them. Also, Morpholinos were described as synthetic RNA, but their structure is quite different so I changed the description to synthetic analog of RNA.

JonMoulton (talk) 22:05, 9 July 2009 (UTC)

Conflict of interest edit request

• What I think should be changed:
• Why it should be changed:
• References supporting the possible change (format using the "cite" button):

disclosure: Connected Contributor

1) Suggest updating revenue to correct number: $1.145B (2023) The suggested reference for this change is:https://investorrelations.sarepta.com/static-files/0dde1f66-7c40-473e-948c-55579b2450e5

2) Suggest adding a new third paragraph to the "History" section to reflect leadership changes: In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.

The suggested reference for this change is: https://www.marketwatch.com/story/sarepta-therapeutics-names-new-ceo-2017-06-28

3) Suggest editing what is currently the final paragraph to reflect the approval status and indication: In June 2023, the FDA approved Sarepta Therapeutics’ 4th therapy, delandistrogene moxeparvovec-rokl, the first gene therapy to treat DMD. The product was approved under the accelerated approval pathway for 4-5 year olds with a confirmed DMD diagnosis. Accelerated approval requires that the product be further studies to verify its clinical benefit.

The suggested reference for this change is: https://www.cnn.com/2023/06/22/health/fda-sarepta-muscular-dystrophy/index.html

4) Suggest adding a new final paragraph under "Products" to reflect current approved products: In June 2024, the U.S. Food and Drug Administration expanded approval of delandistrogene moxeparvovec to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. The FDA granted traditional approval for non-ambulatory patients and accelerated approval for non-ambulatory patients.

The suggested reference for this change is:https://www.cnn.com/2024/06/20/health/fda-gene-therapy-duchenne-muscular-dystrophy/index.html

10BO740M (talk) 22:28, 27 October 2024 (UTC)

Hello, please declare your conflict of interest, as required by WP:DISCLOSE. Also please provide a source for point 3 above. Many thanks, Axad12 (talk) 08:16, 28 October 2024 (UTC)

clarification provided above. Thank you. 10BO740M (talk) 03:34, 29 October 2024 (UTC)

Hello. Wondering if you need any additional information to consider these updates? Thank you! 10BO740M (talk) 19:53, 4 November 2024 (UTC)

References

 Done Encoded  Talk 💬 21:45, 28 October 2024 (UTC)